ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0424

Incremental Healthcare Costs of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Compared to Asthma: Retrospective Analysis of Commercial Claims Data in the United States (US)

Christopher Bell1, Juliana Meyers2 and Mayank Ajmera2, 1GlaxoSmithKline, Research Triangle Park, NC, 2RTI-Health Solutions, Research Triangle Park, NC

Meeting: ACR Convergence 2021

Keywords: Economics, Eosinophilic Granulomatosus with Polyangiitis (Churg-Strauss), Health Services Research

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Vasculitis – ANCA-Associated Poster (0414–0436)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss Syndrome, is a rare, complex multisystem disorder, characterized by vascular inflammation and multisystem organ damage. EGPA manifests as asthma, chronic rhinosinusitis, blood/tissue eosinophilia, and vasculitis. In part due to its rare nature, there is an absence of real-world data quantifying the healthcare cost of EGPA. This study aims to quantify the incremental healthcare resource utilization (HRU) and costs associated with EGPA as compared to asthma using commercial insurance claims data in the United States (US).

Methods: A retrospective analysis was conducted using the IQVIA PharMetrics Plus Database identifying patients (pts) diagnosed with EGPA between 30 September 2008 and 01 October 2018. Prior to the implementation of ICD-10, EGPA diagnosis was based on published ICD-9-based algorithms.1,2 Post October 2015, EGPA diagnosis was based on ICD-10 code M30.1 (polyarteritis with lung involvement [Churg-Strauss]). The first observed ICD-9/10 claim for EGPA was the index date. An asthma control cohort (ICD-9: 493.X; ICD-10: J45.X) was also identified (date of first asthma claim = index date). Pts in both cohorts were ≥18 years of age with continuous health plan enrollment (6-months pre- and 12-months post-index). Pts in the EGPA cohort were matched to pts in the asthma cohort (matching ratio 1:5) using direct covariate matching (age at index, year of index, gender, geographic region, and Charlson-Comorbidity Index [CCI] score). Results are reported as counts, percentages and means (standard deviation [SD]). Multivariable analysis was conducted to estimate adjusted total, all-cause costs using a generalized linear model (GLM). Statistical comparisons were evaluated at α=0.05 level.

Results: After matching, the EGPA and asthma cohorts consisted of 7,183 and 35,915 pts, respectively. Based on covariate matching, the cohorts were similar in terms of baseline characteristics (mean age: 51 years; 73% female; mean CCI score: 2.8) (Table 1). In the 12-month post-index period, significant differences between the EGPA and asthma cohorts were observed (Table 1) for the following: (1) proportion of pts with asthma-related medication (with exception of short-acting beta-agonists), (2) proportion of pts with ≥1 HRU claim by setting of care (with exception of pharmacy claims); and (3) mean total costs and costs by setting of care. Unadjusted total costs in the 12-month post-index period were $44,404 (82,060) and $24,487 (54,691) in the EGPA and asthma cohorts, respectively (p< 0.001). Adjusted total costs in the 12-month post-index period were $34,004 in the EGPA cohort and $19,552 in the asthma cohort (rate ratio: 1.74; 95% confidence internal: 1.68, 1.79; p< 0.001).

Conclusion: In the 12-month post-index period, HRU and costs were significantly higher for EGPA patients than asthma pts. This study demonstrates the incremental burden of EGPA and highlights the need for effective treatments that reduce the burden of disease and improve patient outcomes.

1Sreih et al. Pharmacoepidemiol Drug Saf 2016;25:1368-74.
2Harrold et al. Pharmacoepidemiol Drug Saf 2004;13:661-7.


Disclosures: C. Bell, GlaxoSmithKline, 3, 11; J. Meyers, None; M. Ajmera, None.

To cite this abstract in AMA style:

Bell C, Meyers J, Ajmera M. Incremental Healthcare Costs of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Compared to Asthma: Retrospective Analysis of Commercial Claims Data in the United States (US) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/incremental-healthcare-costs-of-eosinophilic-granulomatosis-with-polyangiitis-egpa-compared-to-asthma-retrospective-analysis-of-commercial-claims-data-in-the-united-states-us/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incremental-healthcare-costs-of-eosinophilic-granulomatosis-with-polyangiitis-egpa-compared-to-asthma-retrospective-analysis-of-commercial-claims-data-in-the-united-states-us/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology